Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
ChemAxon will provide the core tools to support the pan European initiative.

ChemAxon and the European Lead Factory have announced that ChemAxon will provide the core tools and leads the development of the informatics platform to support the pan European initiative.

ChemAxon will be building a portal to support the crowd-sourcing initiative using its core JChem Base and Marvin components.

The scientific decision process involved in selecting the right proposals from those submitted will be supported by ChemAxon’s Discovery Toolkit, including various fingerprints and physico-chemical property predictors.

The portal will also offer a way for submitters to keep track of their submission’s status and for the consortium’s selection committee to score and analyze submitted proposals.

The Innovative Medicines Initiative (IMI), the world’s largest public-private initiative in the field of pharmaceutical research aims to create a new and unique collaboration of public and private sector.

The research program of up to EUR196 million and named the European Lead Factory, involving small and medium-sized enterprises (SMEs), academic institutions and large pharmaceutical companies, aims to improve the competitiveness of the European pharmaceutical industry, accelerate the drug development process, and strives to develop safer, more effective drugs.

The European Lead Factory was launched by an international consortium of 30 partners, with the only Hungarian participant being ChemAxon Ltd. This partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates unprecedented opportunities for the discovery of new medicines through access to a collection of small molecules contributed by pharmaceutical companies, and a newly synthesized compound collection built by the SMEs and academic institutions.

As a result of this partnership, the new compound library consisting of up to half a million compounds will be accessible to all project partners and to public organizations.

Screening of this compound collection will be performed within the pharmaceutical companies and by a newly established European Screening Centre, which will run state of the art facilities in Scotland and the Netherlands to handle logistics and screening of compound libraries.

If the project proves successful during its initial five year funding period, the partnership aims for a sustainable role in drug discovery in Europe.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Broad Institute Acquires License to all ChemAxon Products and Deploys Across Chemical Biology Platform
License covers ChemAxon’s platform, discovery toolkits and desktop applications for institute-wide use.
Friday, August 20, 2010
ChemAxon Announces new CEO and Head of R&D
Company increases its focus on business development and market position with new appointments.
Tuesday, May 13, 2008
Migrating Chemical Information to New Architectures
New ChemAxon whitepaper discusses the drivers behind the increasing number of pharma and biotech companies moving from traditional proprietary chemical information systems to modern alternatives.
Monday, January 29, 2007
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!